INTERNATIONAL JOURNAL OF SCIENTIFIC DEVELOPMENT AND RESEARCH International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2455-2631 | Impact factor: 8.15 | ESTD Year: 2016
open access , Peer-reviewed, and Refereed Journals, Impact factor 8.15
Action of Thalidomide Drug on Female and Male E/Beta Thalassemia Patients
Authors Name:
Shubhajit Roy
Unique Id:
IJSDR2403009
Published In:
Volume 9 Issue 3, March-2024
Abstract:
The idea of thalidomide drugs being effective in treating beta-thalassemia patients and in this case, beta-thalassemia was successfully treated. Thalidomide, sold under the brand names Contergan and Thalomide, is a medication used to treat cancers (including multiple myeloma) and graft-versus-host disease, as well as skin conditions including complications of leprosy. HIV-associated conditions have been treated with it, but such treatment has been associated with increased virus levels. It is taken orally. In addition to improving hemoglobin count, thalidomide also improved other important factors in patients. The use of this drug as per the data we got by implementing them in thalassemia patients has been recommended with proper dosage. Females generally respond better to this drug than males. Thalidomide, in its entirety, might not be a game-changer, but a temporary treatment for thalassemia that keeps patients on track with hemoglobin counts.
"Action of Thalidomide Drug on Female and Male E/Beta Thalassemia Patients", International Journal of Science & Engineering Development Research (www.ijsdr.org), ISSN:2455-2631, Vol.9, Issue 3, page no.67 - 70, March-2024, Available :http://www.ijsdr.org/papers/IJSDR2403009.pdf
Downloads:
000337363
Publication Details:
Published Paper ID: IJSDR2403009
Registration ID:210271
Published In: Volume 9 Issue 3, March-2024
DOI (Digital Object Identifier):
Page No: 67 - 70
Publisher: IJSDR | www.ijsdr.org
ISSN Number: 2455-2631
Facebook Twitter Instagram LinkedIn